JPS57168000A - Novel 11 beta position substituted steroid derivatives, manufacture, intermediates, use thereof and composition - Google Patents

Novel 11 beta position substituted steroid derivatives, manufacture, intermediates, use thereof and composition

Info

Publication number
JPS57168000A
JPS57168000A JP57000638A JP63882A JPS57168000A JP S57168000 A JPS57168000 A JP S57168000A JP 57000638 A JP57000638 A JP 57000638A JP 63882 A JP63882 A JP 63882A JP S57168000 A JPS57168000 A JP S57168000A
Authority
JP
Japan
Prior art keywords
intermediates
novel
manufacture
composition
beta position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57000638A
Other languages
English (en)
Other versions
JPH0234958B2 (ja
Inventor
Jiyorujiyu Touuchi Jiyan
Kosutoruusu Jieruman
Fuiribeeru Danieru
Dorae Rojie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Publication of JPS57168000A publication Critical patent/JPS57168000A/ja
Publication of JPH0234958B2 publication Critical patent/JPH0234958B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
JP57000638A 1981-01-09 1982-01-07 Novel 11 beta position substituted steroid derivatives, manufacture, intermediates, use thereof and composition Granted JPS57168000A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8100272A FR2497807A1 (fr) 1981-01-09 1981-01-09 Nouveaux derives steroides substitues en 11b, leur proc ede de preparation et leur application comme medicament

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP1066488A Division JPH01279897A (ja) 1981-01-09 1989-03-20 新規な１１β位置換ステロイド誘導体の製造中間体

Publications (2)

Publication Number Publication Date
JPS57168000A true JPS57168000A (en) 1982-10-16
JPH0234958B2 JPH0234958B2 (ja) 1990-08-07

Family

ID=9253984

Family Applications (2)

Application Number Title Priority Date Filing Date
JP57000638A Granted JPS57168000A (en) 1981-01-09 1982-01-07 Novel 11 beta position substituted steroid derivatives, manufacture, intermediates, use thereof and composition
JP1066488A Granted JPH01279897A (ja) 1981-01-09 1989-03-20 新規な１１β位置換ステロイド誘導体の製造中間体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP1066488A Granted JPH01279897A (ja) 1981-01-09 1989-03-20 新規な１１β位置換ステロイド誘導体の製造中間体

Country Status (22)

Country Link
US (4) US4386085A (ja)
EP (1) EP0057115B1 (ja)
JP (2) JPS57168000A (ja)
KR (1) KR870001936B1 (ja)
AU (2) AU550334B2 (ja)
BG (1) BG60768B2 (ja)
CA (1) CA1193246A (ja)
DE (2) DE3262580D1 (ja)
DK (1) DK166680B1 (ja)
ES (2) ES8305786A1 (ja)
FI (1) FI77872C (ja)
FR (1) FR2497807A1 (ja)
GE (1) GEP19960479B (ja)
HU (1) HU185158B (ja)
IE (1) IE52595B1 (ja)
LT (1) LT2618B (ja)
MD (1) MD207C2 (ja)
NL (1) NL300001I2 (ja)
PT (1) PT74263A (ja)
SG (1) SG45987G (ja)
SU (1) SU1447289A3 (ja)
ZA (1) ZA8231B (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59157099A (ja) * 1983-02-18 1984-09-06 シエ−リング・アクチエンゲゼルシヤフト １１β―アリール―エストラジエン及びその製法
JPS6118798A (ja) * 1984-06-29 1986-01-27 ルセル‐ユクラフ 新規の１１β位置換ステロイド誘導体、それらの製造方法及びそれらの薬剤としての使用
JPS61183296A (ja) * 1985-02-07 1986-08-15 シエーリング・アクチエンゲゼルシヤフト １１β―フェニル―ゴナン及びその製法
JPS61194096A (ja) * 1985-02-22 1986-08-28 シエーリング・アクチエンゲゼルシヤフト １１β‐アリール‐エストラジエン、その製法及びこれを含有する抗ゲスターゲン及び抗糖質コルチコイド製剤
JP2002505334A (ja) * 1998-03-06 2002-02-19 リサーチ・トライアングル・インスティチュート アゴニスト又はアンタゴニストホルモン特性を有する２０−ケト−１１β−アリールステロイドとその誘導体
JP2006516289A (ja) * 2003-01-22 2006-06-29 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク ミフェプリストンおよびその誘導体のヘッジホッグタンパク質シグナリング経路調節剤としての新規な使用ならびにその適用
JP2007210994A (ja) * 1999-09-02 2007-08-23 Shanghai Zhongxi Pharmaceutical Co Ltd ステロイド類、それらの調製、それらの薬学的組成物およびこの化合物の使用

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978657A (en) * 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2640977A2 (en) * 1982-06-11 1990-06-29 Roussel Uclaf New position-11 substituted 19-norsteroids and their application as medicinal products.
DE3231827A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-17(alpha)-alkinyl-17ss-hydroxy-4,9(10)- estradien-3-on-derivate, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3231828A1 (de) * 1982-08-24 1984-03-01 Schering AG, 1000 Berlin und 4709 Bergkamen 17(alpha)-alkinyl-3,3-alkylendioxy-5(alpha),10(alpha)-epoxy-9(11)-estren-17(beta)-ol-derivate, verfahren zu deren herstellung und deren verwendung zur weiterverarbeitung
EP0116974B1 (de) * 1983-02-18 1986-10-29 Schering Aktiengesellschaft 11-Beta-Aryl-Estradiene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
DE3320580A1 (de) * 1983-06-03 1984-12-06 Schering AG, 1000 Berlin und 4709 Bergkamen D-homo-4,9,16-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
NO162241C (no) * 1983-06-14 1989-11-29 Roussel Uclaf Nye, radioaktive estradienderivater merket med jod125, fremgangsmaate ved deres fremstilling og deres anvendelse vedradioimmunologisk undersoekelse og mengdebestemmelse av steroider i biologiske vaesker.
FR2549067B1 (fr) * 1983-06-14 1985-12-27 Roussel Uclaf Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques
FR2548192B1 (fr) * 1983-06-20 1985-11-22 Roussel Uclaf Derives estradieniques radioactifs marques a l'iode, leur procede de preparation et leur application aux dosages radioimmunologiques
DE3446661A1 (de) * 1984-12-18 1986-06-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 13(alpha)-alkyl-17(beta)-(3-acyloxypropyl)-gonane
ES8502612A1 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
IT1212835B (it) * 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
DE3347126A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5116830A (en) * 1984-08-17 1992-05-26 Sri International Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
DE3438500C1 (de) * 1984-10-18 1986-05-28 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung 11ß-substituierter Δ↑9↑-19-Norsteroide
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
AU580843B2 (en) * 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
GB8513723D0 (en) * 1985-05-31 1985-07-03 Erba Farmitalia 11-beta substituted steroids
DE3531903A1 (de) * 1985-09-05 1987-03-12 Schering Ag Oxytocin und antigestagen zur einleitung der geburt bzw. zum therapeutischen abbruch der graviditaet
DE3533175A1 (de) * 1985-09-13 1987-03-19 Schering Ag Antigestagene zur verschiebung der endometrialen reifung
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) * 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) * 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
US5446178A (en) * 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
ATE69820T1 (de) * 1987-04-24 1991-12-15 Akzo Nv 11-arylestranderivate und 11-arylpregnanderivate.
JPH085909B2 (ja) * 1987-07-24 1996-01-24 協和醗酵工業株式会社 Ｕｃｙ１００３誘導体
FR2618783B1 (fr) * 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0321010B1 (en) * 1987-12-12 1993-02-03 Akzo N.V. New 11-arylsteroid compounds
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) * 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
FR2643638B1 (fr) * 1989-02-24 1991-06-14 Roussel Uclaf Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
DE3917274A1 (de) * 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
US5276023A (en) * 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651435A1 (fr) * 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
FR2654337B1 (fr) * 1989-11-15 1994-08-05 Roussel Uclaf Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
FR2659233B1 (fr) * 1990-03-06 1994-01-21 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques chez les animaux d'elevage.
DE4018168A1 (de) * 1990-06-01 1991-12-05 Schering Ag Ausgangsverbindungen fuer die herstellung von 10ss-h-steroiden und ein verfahren zur herstellung dieser ausgangsverbindungen
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
JPH0464052U (ja) * 1990-10-05 1992-06-01
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
WO1995017192A1 (en) * 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
FR2718354B1 (fr) * 1994-04-08 1996-05-03 Roussel Uclaf Application des composés antiglucocorticoïde pour la préparation de médicaments destinés à la prévention ou au traitement des manifestations liées au syndrome de sevrage des narcotiques et les compositions les renfermant.
DE4415590A1 (de) * 1994-04-28 1995-11-02 Schering Ag Verfahren zur stereoselektiven Einführung einer Alkinylseitenkette an 11ß-Aryl-substituierten 13alpha-Alkylgonan-17-onen
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
ES2152671T3 (es) 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AU756818B2 (en) * 1998-05-15 2003-01-23 Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid receptor antagonists for the treatment of dementia
CA2330611A1 (en) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
WO1999066915A2 (en) * 1998-06-23 1999-12-29 Southern Illinois University At Carbondale Therapeutic applications of estrogenic carboxylic acids
US20020169205A1 (en) * 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
FR2826004B1 (fr) * 2001-06-13 2008-03-28 Aventis Pharma Sa Procede de preparation de derives estrogenes
EP1285927A3 (de) 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7326697B2 (en) 2002-04-29 2008-02-05 Corcept Therapeutics, Inc. Methods for increasing the therapeutic response to electroconvulsive therapy
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
EP1613640A4 (en) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
KR20060052709A (ko) * 2003-06-20 2006-05-19 바이럴 게노믹스, 인크. 항바이러스 조성물 및 그의 사용 방법
SI1889198T1 (sl) 2005-04-28 2015-02-27 Proteus Digital Health, Inc. Farma-informacijski sistem
US20070105828A1 (en) * 2005-08-19 2007-05-10 Glenmark Pharmaceuticals Limited Novel polymorph form M of mifepristone and process for its preparation
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
JP4382735B2 (ja) 2005-10-06 2009-12-16 独立行政法人科学技術振興機構 神経因性疼痛治療剤
DE102005059222B4 (de) * 2005-12-08 2007-10-11 Bayer Schering Pharma Ag 11ß-Benzaldoximderivate von D-Homoestra-4,9-dien-3-onen
US7763648B2 (en) * 2006-02-17 2010-07-27 Janssen Pharmaceutica N.V. Oxa-steroids derivatives as selective progesterone receptor modulators
US20070270393A1 (en) * 2006-02-17 2007-11-22 Theresa Buckley Methods and compositions for modulation of sleep cycle
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
CA2674440A1 (en) * 2007-01-17 2008-07-24 Repros Therapeutics Inc. Methods for improved stability of steroid derivatives
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
WO2010095940A2 (en) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Glutathione-based drug delivery system
NZ596876A (en) 2009-05-06 2014-01-31 Lab Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
JP5894143B2 (ja) 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
EP2868320A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for the treatment of human cells
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
CN107635562A (zh) 2015-05-18 2018-01-26 拜耳医药股份有限公司 选择性孕酮受体调节剂（sprm）方案
EP3335043B1 (en) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
CN108713023B (zh) 2015-12-23 2021-10-26 欧瑞克制药公司 糖皮质激素受体抑制剂
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
SI3523315T1 (sl) * 2016-10-07 2021-08-31 Oric Pharmaceuticals, Inc. Inhibitor glukokortikoidnega receptorja
JP2020500198A (ja) * 2016-11-17 2020-01-09 サイトーＣｙｔｏｏ 骨格筋肥大誘発剤
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS
CN108070016B (zh) * 2017-12-29 2020-07-07 广西万德药业有限公司 甾体环氧异构体的循环利用方法
EP4076470A4 (en) * 2019-12-21 2023-11-22 Corcept Therapeutics Incorporated DIFFERENTIAL TREATMENT AND DIAGNOSIS BETWEEN ACTH-DEPENDENT CUSHING SYNDROME AND ACTH-INDEPENDENT CUSHING SYNDROME
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
KR20220149828A (ko) 2021-04-30 2022-11-09 삼성전자주식회사 반도체 소자
WO2023000135A1 (en) * 2021-07-19 2023-01-26 Context Biopharma Inc. Processes of making onapristone and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3190796A (en) * 1963-04-25 1965-06-22 Upjohn Co Process for inhibiting the growth of micrococcus agilis with 11beta-hydroxy-11-(2-pyridylmethyl)-pregnane-3, 20-dione
FR2377417A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides substitues en 11b, ainsi que leur procede de preparation
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59157099A (ja) * 1983-02-18 1984-09-06 シエ−リング・アクチエンゲゼルシヤフト １１β―アリール―エストラジエン及びその製法
JPH0518837B2 (ja) * 1983-02-18 1993-03-15 Schering Ag
JPS6118798A (ja) * 1984-06-29 1986-01-27 ルセル‐ユクラフ 新規の１１β位置換ステロイド誘導体、それらの製造方法及びそれらの薬剤としての使用
JPS61183296A (ja) * 1985-02-07 1986-08-15 シエーリング・アクチエンゲゼルシヤフト １１β―フェニル―ゴナン及びその製法
JPH0437080B2 (ja) * 1985-02-07 1992-06-18 Schering Ag
JPS61194096A (ja) * 1985-02-22 1986-08-28 シエーリング・アクチエンゲゼルシヤフト １１β‐アリール‐エストラジエン、その製法及びこれを含有する抗ゲスターゲン及び抗糖質コルチコイド製剤
JP2002505334A (ja) * 1998-03-06 2002-02-19 リサーチ・トライアングル・インスティチュート アゴニスト又はアンタゴニストホルモン特性を有する２０−ケト−１１β−アリールステロイドとその誘導体
JP2010120973A (ja) * 1998-03-06 2010-06-03 Research Triangle Inst アゴニスト又はアンタゴニストホルモン特性を有する２０−ケト−１１β−アリールステロイドとその誘導体
JP2007210994A (ja) * 1999-09-02 2007-08-23 Shanghai Zhongxi Pharmaceutical Co Ltd ステロイド類、それらの調製、それらの薬学的組成物およびこの化合物の使用
JP2006516289A (ja) * 2003-01-22 2006-06-29 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク ミフェプリストンおよびその誘導体のヘッジホッグタンパク質シグナリング経路調節剤としての新規な使用ならびにその適用

Also Published As

Publication number Publication date
AU7929682A (en) 1982-07-15
EP0057115A2 (fr) 1982-08-04
SG45987G (en) 1987-11-13
US4519946A (en) 1985-05-28
MD207C2 (ro) 1995-12-31
ES517764A0 (es) 1983-12-01
KR870001936B1 (ko) 1987-10-22
DE3262580D1 (en) 1985-04-25
GEP19960479B (en) 1996-07-22
DK4082A (da) 1982-07-10
BG60768B2 (bg) 1996-02-29
NL300001I2 (nl) 2000-08-01
US4386085A (en) 1983-05-31
DK166680B1 (da) 1993-06-28
CA1193246A (fr) 1985-09-10
PT74263A (fr) 1982-02-01
US4634695A (en) 1987-01-06
ES508588A0 (es) 1983-04-16
AU550334B2 (en) 1986-03-20
FI77872B (fi) 1989-01-31
LT2618B (lt) 1994-04-25
MD207B1 (ro) 1995-05-31
IE820044L (en) 1982-07-09
SU1447289A3 (ru) 1988-12-23
KR840000581A (ko) 1984-02-25
AU579211B2 (en) 1988-11-17
DE19975073I2 (de) 2004-01-08
HU185158B (en) 1984-12-28
JPH01279897A (ja) 1989-11-10
ES8401498A1 (es) 1983-12-01
DE19975073I1 (de) 2000-03-09
EP0057115B1 (fr) 1985-03-20
FI820042L (fi) 1982-07-10
JPH0466879B2 (ja) 1992-10-26
IE52595B1 (en) 1987-12-23
ES8305786A1 (es) 1983-04-16
ZA8231B (en) 1982-11-24
NL300001I1 (nl) 2000-04-03
US4447424A (en) 1984-05-08
AU5123685A (en) 1986-04-17
FI77872C (fi) 1989-05-10
JPH0234958B2 (ja) 1990-08-07
EP0057115A3 (en) 1982-09-29
FR2497807A1 (fr) 1982-07-16
FR2497807B1 (ja) 1983-07-29

Similar Documents

Publication Publication Date Title
JPS57168000A (en) Novel 11 beta position substituted steroid derivatives, manufacture, intermediates, use thereof and composition
CY1291A (en) Androstane 17 beta carbothioates
ZA83982B (en) 3-ceto delta 4,9 19-nor steroid derivatives,their preparation their use as medicaments,the compositions containing them and the intermediates thus obtained
NZ200586A (en) 1,2-diaminocyclobutene-3,4-dione derivatives and intermediates
GB2102806B (en) 26,26,26,27,27,27-hexafluoro-1 ,25-dihydroxy-cholecalciferol and derivatives thereof
NZ189705A (en) Benzophenone-hydrazone derivatives and pesticidal compositions intermediates
JPS57183767A (en) Novel thiazole derivative, manufacture, pharmacological medicine containing same and use as medicine
NZ191900A (en) 24,24-difluoro-1alpha,25-dihydroxycholecalciferol,24,24-difluoro-1alpha,25,-dihydroxy-5,6-trans-cholecalciferol and intermediates;pharmaceutical compositions
JPS57205368A (en) Ceramic composition
GB2093679B (en) Dessert composition
ZA825793B (en) Dispersing composition
NZ191229A (en) Phenyliminomethyl-pyridine derivatives and pesticidal compositions intermediates
GB8431119D0 (en) Anti-arteriosclerotic composition
DE3261485D1 (en) Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof
GB2051818B (en) Derivative of 1 ,25-dihydroxy-cholecalciferol
JPS57181100A (en) Manufacture of 17 alpha-hydroxy-pregn-4-ene- 3,20-dione derivatives
DE3269373D1 (en) Beta alloys with improved properties
JPS57156357A (en) Sulfur-aggregate composition and manufacture
JPS57181007A (en) Local drug composition
DE3273985D1 (en) Steroid intermediates substituted at position 11, and process for their preparation
JPS57176938A (en) Amido derivative, manufacture and agricultural composition containing same
JPS57188456A (en) Ceramic composition
JPS57158761A (en) 4(5)-alkylthioimidazole derivative, manufacture and medicinal composition
JPS57146191A (en) Control rod supporter
ZA825702B (en) Novel phenoxyphenylamino acid derivatives, the production thereof, composition containing the and use thereof